RxDoctor Payments Data

Shu Ying Hsieh

Family · Mesa, AZNPI 1912149147

Payments from drug & device makers

$8,117in general payments, 2019–2025

Across 407 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$965
  • Biohaven Pharmaceuticals, Inc.$917
  • AbbVie$838
  • Novo Nordisk$764
  • Amgen$502
  • Mylan Specialty L.p.$446
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$80010%
  • Food & beverage$7,31790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,117 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$178,846
Medicare patients
323
Services billed
3,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$49,237
OzempicSemaglutide41$45,015
FarxigaDapagliflozin Propanediol47$39,803
ProliaDenosumab21$36,615
MounjaroTirzepatide21$26,746
XareltoRivaroxaban12$16,830
Repatha SyringeEvolocumab12$11,020
Tresiba Flextouch U-200Insulin Degludec16$10,147
Humalog Kwikpen U-100Insulin Lispro14$7,483
Rosuvastatin Calcium233$4,123
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,393
Levothyroxine Sodium299$2,719
SynthroidLevothyroxine Sodium35$2,568
Valsartan43$1,963
Amlodipine Besylate293$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$415$49,23756 claims
Novo NordiskOzempic$764$45,01541 claims
AstraZenecaFarxiga$965$39,80347 claims
AmgenProlia$502$36,61521 claims
Lilly USA, LLCMounjaro$242$26,74621 claims
Johnson & JohnsonXarelto$98$16,83012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,719299 claims
AbbVieSynthroid$838$2,56835 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$21$1,57413 claims
PfizerPaxlovid$225$1,36713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →